Ovid Therapeutics director files Form 3 report

Ovid Therapeutics Inc. director Anna Greka filed a Form 3, which is an initial statement of beneficial ownership for insiders.

Rhea-AI Filing Summary

Ovid Therapeutics Inc. director Anna Greka filed a Form 3, which is an initial statement of beneficial ownership for insiders. In this excerpt, no common stock or derivative transactions are reported, and the transaction summary shows zero buys, sells, exercises, gifts, or tax withholdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OVID Form 3 filing by Anna Greka report?

The Form 3 for Ovid Therapeutics (OVID) lists director Anna Greka as a reporting person. The excerpt shows no common stock or derivative transactions and serves as an initial beneficial ownership statement for this insider under SEC rules.

Does the OVID Form 3 show any insider buying or selling?

No, the Form 3 excerpt for Ovid Therapeutics (OVID) shows zero insider buys and zero sells. The transaction summary fields, including buyCount and sellCount, are all reported as 0, indicating no trades are disclosed here.

Are any stock options or derivatives reported in this OVID Form 3?

No derivative positions are reported for Ovid Therapeutics (OVID) in this Form 3 excerpt. The derivativeSummary is empty and derivativeTransactionCount is 0, meaning no option, warrant, or other derivative transactions are shown in the provided data.

Who is the reporting person on the OVID Form 3 filing?

The reporting person is Anna Greka, identified as a director of Ovid Therapeutics Inc. The reportingPersons section flags her as a director and not a ten percent owner, establishing her insider status for SEC beneficial ownership reporting.

Does the OVID Form 3 indicate any gifts or tax-withholding transactions?

No, the Form 3 excerpt for Ovid Therapeutics (OVID) shows giftCount and taxWithholdingCount as 0. This indicates there are no reported gifts of shares or shares withheld for taxes in the visible portion of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Greka Anna

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/15/2026

3. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jeffrey Rona, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)